Boston Scientific is the latest company to have its earnings impacted by staffing shortages and the disruptions caused by the Omicron variant. The Marlborough, MA-based company did not meet consensus for 1Q22 guidance and full year 2022 guidance.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,